New combo therapy aims to prevent breast cancer return

NCT ID NCT05996107

First seen Feb 01, 2026 · Last updated Apr 25, 2026 · Updated 9 times

Summary

This study is for women with a high-risk type of breast cancer (HR+/HER2-). It tests whether adding the drug ribociclib to standard radiation therapy after surgery is safe and tolerable. About 30 participants will take ribociclib daily for up to 6 weeks while receiving radiation. The goal is to find the best dose and see if this combination can help prevent the cancer from coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UHCMC Seidman Cancer Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Michigan Health West

    RECRUITING

    Wyoming, Michigan, 49519, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.